Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing

Lancet Oncol. 2020 Mar;21(3):343-344. doi: 10.1016/S1470-2045(20)30010-3. Epub 2020 Mar 2.

Authors

Navid Hafez¹, Zenta Walther², Joseph P Eder¹, Jeffrey L Sklar², Scott N Gettinger¹, Karin E Finberg², Sarah B Goldberg³

Affiliations

¹ Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA.
² Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.
³ Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA. Electronic address: [email protected].

PMID: 32950226
DOI: 10.1016/S1470-2045(20)30010-3

No abstract available

MeSH terms

Humans
Molecular Targeted Therapy / trends
Neoplasms / drug therapy*
Neoplasms / epidemiology
Neoplasms / genetics
Neoplasms / pathology
Oncology Service, Hospital / trends*
Precision Medicine / trends*